(NASDAQ: CNTX) Context Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Context Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CNTX's revenue for 2028 to be $105,375,950, with the lowest CNTX revenue forecast at $105,375,950, and the highest CNTX revenue forecast at $105,375,950. On average, 1 Wall Street analysts forecast CNTX's revenue for 2029 to be $451,839,300, with the lowest CNTX revenue forecast at $451,839,300, and the highest CNTX revenue forecast at $451,839,300.
In 2030, CNTX is forecast to generate $858,973,651 in revenue, with the lowest revenue forecast at $858,973,651 and the highest revenue forecast at $858,973,651.